lithospermic acid B

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Lithospermic Acid B 是一种从丹参提取物中提取的水溶性抗氧化剂。具有显着的抗氧化作用；抗血小板聚集、抗凝、抗血栓作用。

lithospermic acid B is a water-soluble antioxidant from Salvia extract. It plays significant role of antioxidant effect; antiplatelet aggregation anticoagulant and antithrombotic effect.

Salvianolic acid B (SA-B) 1 and 10 micromol/L decrease the cell active TGF-beta1 secretion by 63.3 % and 15.6 % of the control, down-regulat pro-collgen alpha1(I) mRNA expression to 77.0% and 51.8% respectively (P<0.05). SA-B 1 and 10 micromol/L also inhibit MAPK activity by 1 to 2 fold respectively.The degradation of Salvianolic acid B is temperature dependent. It was stable at 4oC for 30 h in aqueous solution. However, decomposition of Salvianolic acid B aqueous solution occurres automatically at 25oC, and is enhanced at 37, 65 and 100oC. On the other hand, Salvianolic acid B is also stable at 4, 25 and 37oC for 30 h in TPA (total phenolic acids).Salvianolic acid B is stable for 30 h in buffered phosphate aqueous solutions at pH 1.5, 3.0 and 5.0. With an increase of pH from the neutral, the stability of Sal B decreased.

Salvianolic acid B (SalB) (5 mg · kg-1 · h-1) significantly attenuates LPS-induced pulmonary microcirculatory disturbance, including the increase in leukocyte adhesion and albumin leakage. In addition, LPS increases pulmonary tissue wet-to-dry weight ratio and tumor necrosis factor [alpha] and interleukin 8 levels in plasma and bronchoalveolar lavage fluid enhances the expression of E-selectin, intercellular adhesion molecule 1, myeloperoxidase, MMP-2, and MMP-9, whereas it decreases the expression of AQP-1 and AQP-5 in pulmonary tissue, all of which are attenuated by SalB pretreatment. SalB administration (10 mg/kg) significantly ameliorate the Aβ25-35 peptide-induced memory impairment in the passive avoidance task (P<0.05). SalB treatment also reduced the number of activated microglia and astrocytes that are observed during the inflammatory reaction after the administration of the Aβ25-35 peptide. Moreover, SalB markedly reduce inducible nitric oxide synthase and cyclooxygenase-2 expression levels and thiobarbituric acid reactive substances, which are increased by the administration of the Aβ25-35 peptide. Furthermore, SalB administration significantly rescue the Aβ25-35 peptide-induced decrease of choline acetyltransferase and brain-derived neurotrophic factor protein levels.

Dan Shen Suan B | Salvianolic acid B

Chromatin/Epigenetic

Sirtuin

SIRT

——

——

121521-90-2

718.61

C36H30O16

>98% (HPLC)

DMSO:25 mg/mL (34.79 mM)

OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1

2-(((2S3S)-4-((E)-3-(1-carboxy-2-(34-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(34-dihydroxyphenyl)-7-hydroxy-23-dihydrobenzofuran-3-carbonyl)oxy)-3-(34-dihydroxyphenyl)propanoic acid

(-20℃)

With Ice Pack

≥ 2 years